PIPELINE
Providing answers at every step of lung cancer patient assessment
*Available for enrolling sites for our clinical utility study
Percepta® Nasal Swab
PERCEPTA® NASAL SWAB
What is the test?
Objective tools are needed to assess the risk of lung cancer in patients with detected lung nodules
What is Percepta Nasal Swab?
It is a first-of-its-kind, office-based genomic test that objectively classifies lung cancer risk in an identified lung nodule of patients that are ever-smokers. The test result can provide guidance on which patients can safely avoid unnecessary invasive procedures or undergo further workup to confirm their diagnosis.
Percepta Nasal Swab uses a simple and convenient nasal brushing to objectively evaluate suspicious lung nodules
Sample collection
A simple nasal swab brushing just past the inferior nasal turbinate is used to collect a sample, which is sent to Veracyte.
Test results
Low risk
Monitor with low dose CT
Moderate risk
Consider non-surgical tissue sampling inclusive of bronchoscopy
High risk
Consider sending patients for direct surgery and/or treatment
Percepta Nasal Swab evidence
CHEST 2021 Oral Presentation
A Nasal Clinical-Genomic Classifier for Assessing Risk of Malignancy in Lung Nodules Demonstrates Accurate Performance Independent of Nodule Size or Cancer Stage
Dr. Carla Lamb reviews data that shows how the Percepta Nasal Swab Classifier for assessing risk of malignancy in lung nodules demonstrated accurate performance independent of nodule size or cancer stage.
The Percepta Nasal Swab test is currently available to select sites as part of a clinical utility study.
Contact us if you’d like to discuss or learn more about Percepta Nasal Swab.
Percepta® Genomic Atlas
PERCEPTA® GENOMIC ATLAS
What is the test?
Treating lung cancer with appropriate targeted therapies can improve outcomes
What is Percepta Genomic Atlas?
Percepta Genomic Atlas is a DNA/RNA next generation sequencing (NGS) tissue-based assay that identifies genomic alterations with a focus on lung cancer related genes.
Percepta Genomic Atlas uses a small amount of fresh tissue collected during the initial bronchoscopy for faster actionable results
Sample collection
Transbronchial needle aspirate (TBNA) or transbronchial lung biopsy (TBB) collected into RNA protect and sent to Veracyte
Next Generation Sequencing panel
54 genes including all guideline recommended genes
ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK 1-3, RET, ROS1
Test results
Guideline recommended targeted treatments and clinical trials
Percepta Genomic Atlas evidence
ATS 2021 Poster Presentation
Identification of Driver Mutations in Transbronchial Needle Aspirates of Suspicious Lung Nodules Concurrent with Diagnostic Bronchoscopy
ATS 2021: This Veracyte poster demonstrates the feasibility of Percepta Genomic Atlas in identifying driver mutations in transbronchial needle aspirates.